Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDFIC 2: Long-term Efficacy and Safety of A4250 in PFIC
NCT03659916Phase 3Completed
- Sponsor
- Ipsen
- Start
- Sep 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC), sponsored by Ipsen. Primary endpoint: Percentage of Positive Pruritus Assessments at 72 weeks. Started Sep 2018; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NCT03659916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659916.